Venture Funding Deals: $65m For Iterum's Antibiotic; Genoa's IPF Drug Nets $62m

Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.